A Phase 2b, Randomized, Double-blind Study to Evaluate the Efficacy of Tralokinumab in Adults With Uncontrolled, Severe Asthma.

Trial Profile

A Phase 2b, Randomized, Double-blind Study to Evaluate the Efficacy of Tralokinumab in Adults With Uncontrolled, Severe Asthma.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jul 2017

At a glance

  • Drugs Tralokinumab (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors AstraZeneca; MedImmune
  • Most Recent Events

    • 30 Jul 2017 Results of PK/PD model pooled data from two phase II studies published in the Clinical Pharmacology and Therapeutics
    • 06 Apr 2017 Last checked against ClinicalTrials.gov record.
    • 18 May 2016 Biomarker analysis results (healthy volunteers (N=20) and patients with asthma on ICS/LABA (N=68) or on ICS/LABA and OCS (N=22)), presented at the 112th International Conference of the American Thoracic Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top